Trial Profile
An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Navitoclax (Primary) ; Trametinib (Primary)
- Indications Colorectal cancer; Gynaecological cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 08 Mar 2024 Planned End Date changed from 9 Jan 2025 to 7 Mar 2025.
- 11 Jan 2024 Planned End Date changed from 15 Jan 2024 to 9 Jan 2025.
- 03 Jan 2024 Planned End Date changed from 31 Dec 2023 to 15 Jan 2024.